BioMed Research International

Volume 2014 (2014), Article ID 614506, 10 pages

http://dx.doi.org/10.1155/2014/614506

Research Article

Mechanisms of Ascorbyl Radical Formation in Human Platelet-Rich Plasma

Kou-Gi Shyu,1,2 Chao-Chien Chang,3,4 Yu-Chieh Yeh,⁴ Joen-Rong Sheu,4,5 and Duen-Suey Chou⁵

¹Division of Cardiology, Shin Kong Wu Ho-Su Memorial Hospital, 95 Wenchang Road, Shihlin Taipei 111, Taiwan

²Graduate Institute of Clinical Medicine, Taipei Medical University, 250 Wu-Hsing Street, Taipei 110, Taiwan

³Department of Cardiology, Cathay General Hospital, 280 Jen Ai Road, Section 4, Taipei 106, Taiwan

⁴Graduate Institute of Medical Sciences, Taipei Medical University, 250 Wu-Hsing Street, Taipei 110, Taiwan

⁵Department of Pharmacology, Taipei Medical University, 250 Wu-Hsing Street, Taipei 110, Taiwan

Received 21 November 2013; Accepted 9 January 2014; Published 17 February 2014

Academic Editor: Philip Aloysius Thomas

Copyright © 2014 Kou-Gi Shyu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Recently, many clinical reports have suggested that the ascorbyl free radical () can be treated as a noninvasive, reliable, real-time marker of oxidative stress, but its generation mechanisms in human blood have rarely been discussed. In this study, we used upstream substances, enzyme inhibitors, and free radical scavengers to delineate the mechanisms of formation in human platelet-rich plasma (PRP). Our results show that the doublet signal was detected in PRP samples by using electron spin resonance, and the hyperfine splitting of the doublet signal was gauss and -factor = 2.00627, which was determined to be the . We observed that the inhibitors of NADPH oxidase (NOX), cyclooxygenase (COX), lipoxygenase (LOX), cytochrome P450 (CYP450), mitochondria complex III, and nitric oxide synthase (NOS), but not xanthine oxidase, diminished the intensity of the signal dose dependently. All enzyme inhibitors showed no obvious antioxidant activity during a Fenton reaction assay. In summary, the obtained data suggest that formation is associated with NOX, COX, LOX, CYP450, eNOS, and mitochondria in human PRP.

1. Introduction

Interest in treating oxidative stress has grown in medicine over the past 2 decades. The oxidative status of a biosystem represents a relative level of oxidation in living organisms and is crucial for understanding numerous human physiological and pathophysiological processes [1]. Overproduction of ROS results in oxidative stress, a pathophysiological process that can damage cell structures and induce cancer, cardiovascular disease, atherosclerosis, hypertension, diabetes mellitus, neurodegenerative diseases, rheumatoid arthritis, and ageing. In contrast, ROS play a physiological role in protection against infectious organisms, in the function of several cellular signalling pathways, and the generation of a mitogenic response at low/moderate concentrations [1]. Oxidative status can be estimated using biochemical assays, such as the 2,2′-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) assay [2], and by measuring the activity of superoxide dismutating enzymes (Mn superoxide dismutase (SOD) and CuZnSOD), catalase (CAT), GSH peroxidase, and reductase [3–5], as well as the level of S-glutathionylation [6]. However, Spasojević suggested that these techniques be supplemented by electron spin resonance (ESR) spectroscopy to enable acquiring data on oxidative status that are more specific [7]. Certain endogenous paramagnetic molecules, such as the ascorbyl free radical (), tocopheryl radical, and melanin radical, are biomarkers of oxidative status that can be detected using ESR spectroscopy [7].

Ascorbic acid is an essential biological component that can be oxidized through a two-step oxidation process involving a free radical intermediate; this oxidation process may be performed by nearly all oxidizing species intrinsic to the biological environment [7]. When using ESR spectroscopy, the concentration of the can be measured using a lower limit of approximately 5 nM with a standard deviation of <1 nM [8]. The characteristics of the are relatively stable and it has a long half-life, indicating that it is the most useful biomarker of oxidative status in living systems [7].

ESR spectroscopy was first applied in detecting the in oxidative status research in 1993 [9]. Thus far, the has been treated as a noninvasive, reliable, real-time biomarker of oxidative stress in various biological samples including plasma, serum, whole blood, cerebrospinal fluid, extracellular fluid, synovial fluid, seminal fluid, tumor, and heart tissue samples [7]; however, the generation mechanisms of the in human blood have rarely been discussed.

Ascorbate (the reduced form of vitamin C) is an important radical scavenger and antioxidant in human plasma. has been detected by ESR in various biological samples including plasma, serum, whole blood, cerebrospinal fluid, skin, extracellular fluid, synovial fluid, gastric mucosa, seminal fluid, tumors, heart tissue, and others [7]. We recently applied ESR spectroscopy in detecting the to investigate the mechanisms of oxidative stress caused by lymphedema in mice [10]. In this study, we used upstream substances, enzyme inhibitors, and free radical scavengers to delineate the mechanisms of formation in human platelet-rich plasma (PRP).

2. Materials and Methods

2.1. Materials

AA861, allopurinol, antimycin, arachidonic acid (AA), baicalein, CAT, clotrimazole, dimethyl sulfoxide (DMSO), diphenyleneiodonium (DPI), ethylenediaminetetraacetic acid, hemoglobin, indomethacin, NG-nitro-L-arginine methyl ester (L-NAME), quinacrine, and SOD were purchased from Sigma Chemical (St. Louis, MO, USA). L(+)-ascorbic acid was purchased from Wako Pure Chemical Industries (Osaka, Japan).

2.2. Human Blood Collection Procedure

This study was approved by the Institutional Review Board of Taipei Medical University and conformed to the principles outlined in the Helsinki Declaration. All human volunteers provided informed consent to participate.

2.3. Preparation of Human Blood Components

Whole blood was collected from healthy human volunteers who had taken no medicine during the preceding 2 wk and was mixed with acid/citrate/glucose. After centrifugation at 120 g for 10 min at room temperature, the supernatant (PRP) was supplemented with PGE₁ (0.5 M) and heparin (6.4 IU/mL) and then incubated for 10 min at 30°C and centrifuged at 500 g for 10 min. The supernatant was platelet-poor plasma (PPP) and was used in subsequent experiments.

2.4. Isolation of Red Blood Cells

Whole blood was centrifuged at 650 g for 5 min. Plasma was removed carefully and the white buffy layer was completely removed through aspiration using a pipette with utmost care. The red blood cells (RBCs) were then washed three additional times with Tyrode’s solution.

2.5. Measurement of the Ascorbyl Free Radical in Platelet-Rich Plasma Using Electron Paramagnetic Resonance Spectrometry

The ESR method involved using a Bruker EMX ESR spectrometer (Bruker Instruments Inc., Billerica, MA, USA) as described previously [11]. The PRP was prewarmed to 37°C for 2 min, and enzyme inhibitors or other reagents were then added. ESR spectra were recorded at room temperature by using a quartz flat cell designed for aqueous solutions. ESR spectrometry was conducted under the following conditions: 20 mW of power at 9.78 GHz, with a scan range of 100 G and a receiver gain of . The modulation amplitude, sweep time, and time constant are provided in the figure legends.

2.6. Fenton Reaction Model System with Electron Paramagnetic Resonance Detection of the Hydroxyl Radical

The hydroxyl radical generated in a standard Fenton reaction was trapped using DMPO according to the method previously described [12]. A Fenton reaction solution (50 M FeSO₄ + 500 M H₂O₂) was pretreated with a solvent control (0.6% DMSO) or reagent (10 M). The ESR spectra were recorded after precisely 3 min.

2.7. Statistical Analysis

The experimental results are expressed as the mean ± SEM and are accompanied by the number () of observations. The data were assessed using an analysis of variance (ANOVA). When this analysis indicated significant differences among the group means, each group was compared using the Newman-Keuls method. A value <0.05 was considered statistically significant.

3. Results

3.1. Electron Spin Resonance Investigations of Free Radicals Formed in Human Blood Components

Free radical signals were detected using ESR in human PPP, PRP, RBCs, and whole blood. A doublet signal radical was observed in PPP and PRP, but not in RBCs or whole blood (Figure 1(a)). PRP exhibited the strongest signal among the human blood components and was used in subsequent experiments. The hyperfine splitting and -factor of this doublet signal were 1.88 G and 2.00627, respectively. In each instance, the signals exhibited doublet peaks and a line width of approximately 4 G. The radical species was identified to be ascorbyl based on the close similarity of the hyperfine coupling constants and -factor of the observed signal to those of published data [13, 14]. No notable oxygen-derived free radicals were detected in this study, probably because of the presence of ascorbic acid and other antioxidants in human PRP.

(a)

(b)

Figure 1: Free radical doublet (a) detected using ESR spectroscopy in (A) PPP, (B) PRP, (C) RBCs, and (D) whole blood. The ESR signal was examined at room temperature, and the following instrument parameters were used in ESR spectroscopy: standard frequency (X-band): 9 GHz; microwave power: 20 mW; modulation frequency: 100 kHz; time constant: 163.84 ms; conversion time: 40.96 ms; receiver gain: ; and the number of data X-scans: 4. The free radical doublet is marked with arrows: “”. Effect of ascorbic acid on the radical formation in human PRP. The intensity of the radical obtained from the reaction of PRP (approximately  cells/mL, control) and 30 M, 100 M, 300 M, and 1000 M ascorbic acid in the presence of 100 mM DMPO. ESR analysis was exactly 30 s after the final addition. ESR spectra are labeled to show their components: DMPO- adduct (*). The values of the ESR signal intensity in the bar chart (b) are shown as the means ± SEM (). compared with the control. The instrument parameters were identical to those shown in (a).

3.2. Effect of Exogenous Ascorbic Acid on the Radical Formation in Human Platelet-Rich Plasma

To confirm that the radical was a typical , we added exogenous ascorbic acid to human PRP. The intensity of the radical induced by exogenous ascorbic acid increased dose dependently (Figure 1(b)).

3.3. Effect of Superoxide and the Nitric Oxide Scavenger on Ascorbyl Free Radical Formation in Human Platelet-Rich Plasma

We propose that the is a secondary radical; therefore, we determined which types of primary radical may be involved in the formation of this radical species. The effects of superoxide and the nitric oxide scavenger were examined on the radical formation, as shown in Figure 2. The signal formed by PRP was arbitrarily designated 100% and was inhibited by the superoxide scavenger (120 U/mL of SOD and 1000 U/mL of CAT) and nitric oxide scavenger (1 g/mL of hemoglobin) to 26.1% () and 13.5% (), respectively. This result indicates that superoxide and nitric oxide may be primary radicals that induce formation.

(a)

(b)

Figure 2: Effect of superoxide and the nitric oxide scavenger on formation in human PRP. ESR spectra (a) obtained from the reaction of (A) PRP (approximately  cells/mL) and (B) superoxide scavenger (120 U/mL SOD and 1000 U/mL CAT) and the (C) nitric oxide scavenger (1 g/mL of hemoglobin) in the presence of 100 mM DMPO for 3 min. The ESR spectra are labeled to show their components: DMPO- adduct (*). The ESR signal intensity rates in the bar chart (b) are shown as the means ± SEM (). , compared with the control. The instrument parameters were identical to those shown in Figure 1(a).

3.4. Effect of the NADPH Oxidase Inhibitor on Ascorbyl Free Radical Formation in Human Platelet-Rich Plasma

It was reported that NOX on the cell membrane of leucocytes may be the primary source of superoxide formation in blood [15]. To investigate the involvement of NOX in formation in PRP, we used DPI as a NOX nonselective inhibitor. The signal of a solvent control group was arbitrarily designated 100% and was dose dependently inhibited by DPI (3 M = 17.7%, ; 10 M = 23.8%, , Figure 3(a)). This result indicates that NOX may be involved in the formation of in PRP.

(a)

(b)

(c)

Figure 3: Effect of the NOX inhibitor (a), XO inhibitor (b), and NOS inhibitor (c) on formation in human PRP (approximately  platelets/mL). The ESR signal intensity rates in the bar chart are expressed as the means ± SEM (). , compared with the solvent control. The instrument parameters were identical to those shown in Figure 1(a).

3.5. Effect of the Xanthine Oxidase Inhibitor on Ascorbyl Free Radical Formation in Human Platelet-Rich Plasma

XO is a superoxide-producing enzyme normally present in the serum and lungs [16]. To investigate the involvement of XO in formation in PRP, we used allopurinol as a nonselective XO inhibitor. The signal of a solvent control group was arbitrarily designated 100%, and allopurinol (1–10 M) did not significantly influence formation in PRP (, Figure 3(b)).

3.6. Effect of the Nitric Oxide Synthase Inhibitor on Ascorbyl Free Radical Formation in Human Platelet-Rich Plasma

We determined whether NOS is involved in formation in PRP. We used L-NAME as an NOS inhibitor. The signal of a solvent control group was arbitrarily designated 100% and was inhibited by L-NAME (1–10 M) dose dependently (3 M = 18.6%, ; 10 M = 25.4%, , Figure 3(c)). This result indicates that NOS-derived NO is associated with the formation of in PRP.

3.7. Effect of Arachidonic Acid on Ascorbyl Free Radical Formation in Human Platelet-Rich Plasma

Reactive oxygen species (ROS) are generated by AA metabolites, which are released from the cell membrane. AA-induced ROS generation may occur through the oxidative metabolic processes induced by COX and LOX [11]. AA has also been reported to induce ROS formation through NOX [17, 18]. Our results showed that NOX may be involved in the formation of the in PRP (Figure 3(a)). Therefore, we determined whether AA metabolite pathways are associated with the formation. The signal formed by PRP was, respectively, increased 39.1% () and 62.4% () by 10 M and 100 M AA compared with a solvent control (Figure 4(a)). In addition, the signal of the solvent control group was arbitrarily designated 100% and was inhibited by quinacrine (2.5–10 M), a phospholipidase A₂ (PLA₂) inhibitor, dose dependently (5 M = 20.9%, ; 10 M = 26.2%, , Figure 4(b)). This result indicates that AA metabolite pathways are associated with the formation of the in PRP.

(a)

(b)

Figure 4: Effect of AA (a) and the PLA₂ inhibitor (b) on formation in human PRP (approximately  platelets/mL). The ESR signal intensity and data in the bar chart are expressed as the means ± SEM (). , compared with the solvent control group. The instrument parameters were identical to those shown in Figure 1(a).

3.8. Effect of the Cyclooxygenase Inhibitor on Ascorbyl Free Radical Formation in Human Platelet-Rich Plasma

In downstream pathways of the AA metabolism, COX [19], P450 [20], and LOX [21] are vital sources of extracellular ROS release. To investigate the involvement of COX in formation in PRP, we used indomethacin as a nonselective COX inhibitor. The signal of a solvent control group was arbitrarily designated 100%; 3 and 10 M indomethacin produced a 13.4% () and 14.5% () reduction of the signal, respectively. However, the signal was not significantly changed when a low dose (1 M) of indomethacin (Figure 5(a)) was used. This result suggests that COX may be involved in the formation of the in PRP.

(a)  

(b)

(c)

Figure 5: Effect of the COX inhibitor (a), LOX inhibitor (b), and CYP450 inhibitor (c) on formation in human PRP (approximately  platelets/mL). The ESR spectra are labeled to show their components: DMPO- adduct (*). The ESR signal intensity rates and data in the bar chart are expressed as the means ± SEM (). , compared with the solvent control. The instrument parameters were identical to those shown in Figure 1(a).

3.9. Effect of the Lipoxygenase Inhibitor on Ascorbyl Free Radical Formation in Human Platelet-Rich Plasma

To investigate the involvement of LOX in formation in PRP, we used AA861 as a nonselective LOX inhibitor. The signal of a solvent control group was arbitrarily designated 100% and was inhibited by AA861 (1–10 M) dose dependently (10 M = 25.7%, , Figure 5(b)). This result suggests that LOX may also be involved in the formation of in PRP.

3.10. Effect of the P450 Inhibitor on Ascorbyl Free Radical Formation in Human Platelet-Rich Plasma

To investigate the involvement of P450 in formation in PRP, we used clotrimazole as a nonselective P450 inhibitor. As shown in Figure 5(c), 1 and 10 M clotrimazole produced 13.7% () and 19.5% () depressions of the signal, respectively.

3.11. Influence of the Mitochondrial Respiratory Chain on Ascorbyl Free Radical Formation in Human Platelet-Rich Plasma

In the mitochondrial respiratory chain, some electrons may leak to oxygen, partially reducing oxygen to a superoxide anion [22]. We determined whether oxidative stress induced by the mitochondrial respiratory chain is associated with formation in PRP. We used antimycin as a mitochondrial complex III inhibitor. The signal of a solvent control group was arbitrarily designated 100%, and 10, 30, and 100 M antimycin, respectively, produced 19.2% (), 23.3% (), and 32.5% () depressions of the signal (Figure 6). This indicates that mitochondrial respiratory chain oxidative stress plays a partial role in formation in PRP.

(a)

(b)

Figure 6: Effect of the mitochondrial complex III inhibitor on formation in human PRP. The ESR spectra show (a) the effect of a solvent control, (A) 0.6% DMSO, and 10, 30 (data not shown), and (B) 100 M antimycin in the presence of 100 mM DMPO for 30 min on formation in human PRP (approximately  platelets/mL). The ESR spectra are labeled to show their components: DMPO- adduct (*). The ESR signal intensity rate and data shown in the bar chart (b) are expressed as the means ± SEM (). compared with the solvent control. The instrument parameters were identical to those shown in Figure 1.

3.12. Antioxidative Assay of Enzyme Inhibitors

Higashi et al. demonstrated that nordihydroguaiaretic acid, AA-861, and baicalein are LOX inhibitors and also have antioxidant activity [23]. However, Pallast et al. showed that AA-861 inhibits both 12/15-LOX and 5-LOX but does not have antioxidant activity [24]. Therefore, we selected AA-861 as a LOX inhibitor in this study. However, some enzyme inhibitors used in this study still potentially elicit antioxidative effects and inhibit signal production. To exclude this possibility, we used the Fenton reaction assay to determine whether the enzyme inhibitors were also antioxidants. The enzyme inhibitors were divided into lipid-soluble (Figure 7(a)) and water-soluble (Figure 7(b)) groups. Our result showed that DPI (10 M), AA861 (10 M), L-NAME (10 M), allopurinol (10 M), clotrimazole (10 M), indomethacin (10 M), quinacrine (10 M), and antimycin (10 M) did not exhibit significant antioxidative activity in the Fenton reaction assay ().

(a)

(b)

Figure 7: Effect of the fat-soluble (a) and water-soluble (b) enzyme inhibitor on hydroxyl free radical formation in the Fenton reaction. (a) The effect of the Fenton reaction solution (500 M hydrogen peroxide + 50 M FeSO₄, positive control), 0.6% DMSO, 10 M DPI, 10 M AA861, 10 M L-NAME, 10 M allopurinol, 10 M clotrimazole, and 10 M indomethacin in the presence of 150 mM DMPO for 3 min on hydroxyl radical formation. (b) The effect of the Fenton reaction solution (positive control), 10 M quinacrine, and 100 M antimycin in the presence of 150 mM DMPO for 3 min on hydroxyl radical formation. The signal intensity rates and data shown in the bar chart are expressed as the means ± SEM (). compared with the solvent control. The instrument parameters were identical to those shown in Figure 1(a).

4. Discussion

The vascular endothelium plays an essential role in regulating vascular tone, modulating vascular growth, platelet aggregation and coagulation, and inflammation. Therefore, the degree of endothelial dysfunction may predict the outcomes of cardiovascular diseases [25]. Although the precise mechanisms of endothelial dysfunction have not been elucidated, a considerable amount of evidence suggests that increased oxidative stress may play a critical role in this state [26]. Oxidative stress can be described as an “imbalance between proxidants and antioxidants in favor of the proxidants, potentially leading to damage” [27]. Currently, reducing oxidative stress remains a prominent objective for cardiovascular prevention and therapy. However, clear knowledge of its source is required to provide novel perspectives for treatment.

ROS participate in the growth, apoptosis, and migration of vascular smooth muscle cells and in the remodeling of the vessel wall. Each of these responses may contribute to vascular diseases in uncontrolled conditions [28]. Therefore, the sources of ROS may be crucial therapeutic targets of cardiovascular disease.

In this study, we found that signals were observed in PPP and PRP, but not in RBCs or whole blood (Figure 1(a)). A study of ESR spectra of whole blood from normal and tumour bearing patients showed two main lines with values of 4.2 and 2.049 [29]. The authors suggested that the line at may be due to the copper protein ceruloplasmin. In addition, smaller signals were found with values of 2.16, 2.005, and 1.98. We suggest that some paramagnetic species in whole blood with values nearby 2.0 that restrict the signal intensity of ascorbyl radical. Therefore, in this study, we used ESR spectroscopy in detecting the to determine the sources of oxidative stress in human PRP. formation may be induced by nearly all ROS intrinsic to the biological environment, including superoxide radicals, hydroxyl radicals, alkyl peroxyl radicals, lipid peroxyl radicals, peroxynitrite, thiyl radicals, protein radicals, and catalytic metals [7].

In the vasculature wall, ROS are produced by all of the layers, and the major vascular ROS is the superoxide anion, which inactivates NO and, thus, impairs relaxation [30]. Superoxide-generating enzymes involved in increased oxidative stress within vascular tissue include uncoupled NOS, NOX, XO, and mitochondrial superoxide-generating enzymes [31]. In this study, we observed that the AA pathway enzymes, such as COX, LOX, and CYP450, also contributed to the increased oxidative stress in human PRP. However, the XO did not seem to play an important role in this event (Figure 8).

Figure 8: Proposed pathway for the mechanisms of formation in human PRP (; superoxide anion; NO; nitric oxide).

XO is capable of generating superoxide and hydrogen peroxide when supplied with its substrates, xanthine and hypoxanthine, which accumulate during ischemia [32]. Although studies have shown that XO is present in human arterial and venous endothelial cells and can generate sufficient levels of oxygen radicals to trigger endothelial injury, questions remain regarding the role of xanthine and hypoxanthine formation in triggering this process. Because the samples in this study were not subjected to ischemic conditions, we did not observe XO contributing to oxidative stress in human PRP.

NO is released from endothelial cells mainly by eNOS and is a main mediator of endothelium-dependent vasodilatation. When ROS production is increased, tetrahydrobiopterin generation is reduced, causing eNOS to uncouple and produce superoxide; when NO is insufficiently formed or quenched too quickly, the process of atherosclerosis is initiated or accelerated [33]. In pathological conditions, NO may be scavenged by excess ROS generated in blood vessels by vascular NOX [15]. eNOS has been observed not only in the endothelium but also in platelets [34]. Therefore, based on our results, we suggest that platelet eNOS is also a source of ROS in human PRP.

We recently applied ESR spectroscopy in detecting to investigate the oxidative status of lymphedema, suggesting that COX-derived oxidative stress plays a major role in the pathological mechanisms of surgically induced lymphedema [10]. However, in the current study, COX-derived oxidative stress played only a minor role in oxidative stress in human PRP.

5. Conclusion

In this study, we investigated the potential sources of production that contribute to oxidative stress in human PRP. We provide evidence that no single source of can be identified in human PRP, but are typically generated through NOX, COX, LOX, CYP450, eNOS, and mitochondrial superoxide-generating enzyme pathways.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This work was supported by Grants from the National Science Council of Taiwan (NSC97-2320-B-038-016-MY3 and NSC100-2320-B-038-021-MY3) and Shin Kong Wu Ho-Su Memorial Hospital-Taipei Medical University (SKH-TMU-100-12).

References

M. Valko, D. Leibfritz, J. Moncol, M. T. D. Cronin, M. Mazur, and J. Telser, “Free radicals and antioxidants in normal physiological functions and human disease,” International Journal of Biochemistry and Cell Biology, vol. 39, no. 1, pp. 44–84, 2007.

C. Rice-Evans and N. Miller, “Measurement of the antioxidant status of dietary constituents, low density lipoproteins and plasma,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 57, no. 4-5, pp. 499–505, 1997.

A. N. Kokic, Z. Stevic, S. Stojanovic et al., “Biotransformation of nitric oxide in the cerebrospinal fluid of amyotrophic lateral sclerosis patients,” Redox Report, vol. 10, no. 5, pp. 265–270, 2005.

J. B. Pristov, I. Spasojevic, Ž. Mikovic, V. Mandic, N. Cerovic, and M. Spasic, “Antioxidative defense enzymes in placenta protect placenta and fetus in inherited thrombophilia from hydrogen peroxide,” Oxidative Medicine and Cellular Longevity, vol. 2, no. 1, pp. 14–18, 2009.

M. Slavić, I. Appiah, A. Nikolić-Kokić et al., “The anti-oxidative defence system in the isolated rat uterus during spontaneous rhythmic activity,” Acta Physiologica Hungarica, vol. 93, no. 4, pp. 335–339, 2006.

D. M. Townsend, “S-glutathionylation: indicator of cell stress and regulator of the unfolded protein response,” Molecular Interventions, vol. 7, no. 6, pp. 313–324, 2008.

I. Spasojević, “Free radicals and antioxidants at a glance using EPR spectroscopy,” Critical Reviews in Clinical Laboratory Sciences, vol. 48, no. 3, pp. 114–142, 2011.

G. R. Buettner and B. A. Jurkiewicz, “Catalytic metals, ascorbate and free radicals: combinations to avoid,” Radiation Research, vol. 145, no. 5, pp. 532–541, 1996.

G. R. Buettner and B. A. Jurkiewicz, “Ascorbate free radical as a marker of oxidative stress: an EPR study,” Free Radical Biology and Medicine, vol. 14, no. 1, pp. 49–55, 1993.

T. C. Chang, Y. H. Uen, C. H. Chou, J. R. Sheu, and D. S. Chou, “The role of cyclooxygenase-derived oxidative stress in surgically induced lymphedema in a mouse tail model,” Pharmaceutical Biology, vol. 51, no. 5, pp. 573–580, 2013.

M. Edderkaoui, P. Hong, E. C. Vaquero et al., “Extracellular matrix stimulates reactive oxygen species production and increases pancreatic cancer cell survival through 5-lipoxygenase and NADPH oxidase,” American Journal of Physiology, vol. 289, no. 6, pp. G1137–G1147, 2005.

C.-Y. Hsieh, C.-L. Liu, M.-J. Hsu et al., “Inhibition of vascular smooth muscle cell proliferation by the vitamin E derivative pentamethylhydroxychromane in an in vitro and in vivo study: pivotal role of hydroxyl radical-mediated PLCγ1 and JAK2 phosphorylation,” Free Radical Biology and Medicine, vol. 49, no. 5, pp. 881–893, 2010.

H. Sakagami, K. Satoh, H. Ohata et al., “Relationship between ascorbyl radical intensity and apoptosis inducing activity,” Anticancer Research, vol. 16, no. 5 A, pp. 2635–2644, 1996.

C. Vergely, V. Maupoil, M. Benderitter, and L. Rochette, “Influence of the severity of myocardial ischemia on the intensity of ascorbyl free radical release and on postischemic recovery during reperfusion,” Free Radical Biology and Medicine, vol. 24, no. 3, pp. 470–479, 1998.

R. M. Touyz and E. L. Schiffrin, “Reactive oxygen species in vascular biology: implications in hypertension,” Histochemistry and Cell Biology, vol. 122, no. 4, pp. 339–352, 2004.

H. Hemila, “Vitamin C and the common cold,” The British Journal of Nutrition, vol. 67, pp. 3–16, 1992.

C. Kim and M. C. Dinauer, “Impaired NADPH oxidase activity in Rac2-deficient murine neutrophils does not result from defective translocation of p47phox and p67 phox and can be rescued by exogenous arachidonic acid,” Journal of Leukocyte Biology, vol. 79, no. 1, pp. 223–234, 2006.

A. Shiose and H. Sumimoto, “Arachidonic acid and phosphorylation synergistically induce a conformational change of p47(phox) to activate the phagocyte NADPH oxidase,” The Journal of Biological Chemistry, vol. 275, no. 18, pp. 13793–13801, 2000.

W. M. Armstead, R. Mirro, D. W. Busija, and C. W. Leffler, “Postischemic generation of superoxide anion by newborn pig brain,” American Journal of Physiology, vol. 255, no. 2, pp. H401–H403, 1988.

M. Sato, U. Yokoyama, T. Fujita, S. Okumura, and Y. Ishikawa, “The roles of cytochrome P450 in ischemic heart disease,” Current Drug Metabolism, vol. 12, no. 6, pp. 526–532, 2011.

G. Jin, K. Arai, Y. Murata et al., “Protecting against cerebrovascular injury: contributions of 12/15-lipoxygenase to edema formation after transient focal ischemia,” Stroke, vol. 39, no. 9, pp. 2538–2543, 2008.

J. F. Turrens, “Mitochondrial formation of reactive oxygen species,” Journal of Physiology, vol. 552, no. 2, pp. 335–344, 2003.

Y. Higashi, T. Peng, J. Du et al., “A redox-sensitive pathway mediates oxidized LDL-induced downregulation of insulin-like growth factor-1 receptor,” Journal of Lipid Research, vol. 46, no. 6, pp. 1266–1277, 2005.

S. Pallast, K. Arai, X. Wang, E. H. Lo, and K. Van Leyen, “12/15-Lipoxygenase targets neuronal mitochondria under oxidative stress,” Journal of Neurochemistry, vol. 111, no. 3, pp. 882–889, 2009.

V. Schächinger, M. B. Britten, and A. M. Zeiher, “Prognostic impact of coronary vasodilator dysfunction on adverse long- term outcome of coronary heart disease,” Circulation, vol. 101, no. 16, pp. 1899–1906, 2000.

T. Münzel, T. Gori, R. M. Bruno, and S. Taddei, “Is oxidative stress a therapeutic target in cardiovascular disease?” European Heart Journal, vol. 31, no. 22, pp. 2741–2749, 2010.

H. Sies, “Oxidative stress: from basic research to clinical application,” American Journal of Medicine, vol. 91, no. 3, pp. 31S–38S, 1991.

A. Fortuño, G. San José, M. U. Moreno, J. Díez, and G. Zalba, “Oxidative stress and vascular remodelling,” Experimental Physiology, vol. 90, no. 4, pp. 457–462, 2005.

M. A. Foster, T. Pocklington, J. D. B. Miller, and J. R. Mallard, “A study of electron spin resonance spectra of whole blood from normal and tumour bearing patients,” British Journal of Cancer, vol. 28, no. 4, pp. 340–348, 1973.

H. Cai and D. G. Harrison, “Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress,” Circulation Research, vol. 87, no. 10, pp. 840–844, 2000.

T. Münzel, A. Daiber, V. Ullrich, and A. Mülsch, “Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the CGMP-dependent protein kinase,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 8, pp. 1551–1557, 2005.

J. L. Zweier and M. A. H. Talukder, “The role of oxidants and free radicals in reperfusion injury,” Cardiovascular Research, vol. 70, no. 2, pp. 181–190, 2006.

T. Münzel, C. Sinning, F. Post, A. Warnholtz, and E. Schulz, “Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction,” Annals of Medicine, vol. 40, no. 3, pp. 180–196, 2008.

M. W. Radomski, R. M. J. Palmer, and S. Moncada, “An L-arginine/nitric oxide pathway present in human platelets regulates aggregation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 13, pp. 5193–5197, 1990.